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MaBACKGROUND Patients with long QT syndrome (LQTS) are predisposed to life-threatening arrhythmias. A delay in
cardiac repolarization is characteristic of the disease. Pharmacotherapy, implantable cardioverter-defibrillators, and left
cardiac sympathetic denervation are part of the current treatment options, but no targeted therapy for LQTS exists to
date. Previous studies indicate that induced autoimmunity against the voltage-gated KCNQ1 Kþ channels accelerates
cardiac repolarization.
OBJECTIVES However, a causative relationship between KCNQ1 antibodies and the observed electrophysiological ef-
fects has never been demonstrated, and thus presents the aim of this study.
METHODS The authors purified KCNQ1 antibodies and performed whole-cell patch clamp experiments as well as single-
channel recordings on Chinese hamster ovary cells overexpressing IKs channels. The effect of purified KCNQ1 antibodies
on human cardiomyocytes derived from induced pluripotent stem cells was then studied.
RESULTS The study demonstrated that KCNQ1 antibodies underlie the previously observed increase in repolarizing IKs
current. The antibodies shift the voltage dependence of activation and slow the deactivation of IKs. At the single-channel
level, KCNQ1 antibodies increase the open time and probability of the channel. In models of LQTS type 2 (LQTS2) using
human induced pluripotent stem cell-derived cardiomyocytes, KCNQ1 antibodies reverse the prolonged cardiac repo-
larization and abolish arrhythmic activities.
CONCLUSIONS Here, the authors provide the first direct evidence that KCNQ1 antibodies act as agonists on IKs
channels. Moreover, KCNQ1 antibodies were able to restore alterations in cardiac repolarization and most importantly
to suppress arrhythmias in LQTS2. KCNQ1 antibody therapy may thus present a novel promising therapeutic
approach for LQTS2. (J Am Coll Cardiol 2020;75:2140–52) © 2020 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).T he long QT syndrome (LQTS) is responsiblefor a significant proportion of sudden cardiacdeaths (1). Genetic mutations leading to a
loss of function of the cardiac voltage-gated KCNH2
(LQTS type 2 [LQTS2]) or KCNQ1 (LQTS type 1
[LQTS1]) Kþ channels are the most common causes
(2). As a result, the corresponding repolarizing cur-
rents across the channels, IKr and IKs, respectively,
are reduced, which prolongs the cardiacN 0735-1097
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include beta-blockers, left cardiac sympathetic dener-
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AB BR E V I A T I O N S
AND ACRONYM S
AP = action potential
APD = action potential
duration
CHO = Chinese hamster ovary
EAD = early
afterdepolarization
ECG = electrocardiogram
hiPSC-CMC = human induced
pluripotent stem cell-derived
cardiomyocyte
IgG = immunoglobulin G
LQTS1 = long QT syndrome
type 1
LQTS2 = long QT syndrome
type 2
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2141already-occurring VT. In the search for a tailored ther-
apy for LQTS, the KCNQ1 channel has naturally drawn
our attention, given its substantial role in cardiac
repolarization. Consequently, a compound that acti-
vates KCNQ1 channels represents an optimal
approach to restore normal repolarization. In a previ-
ous clinical study, autoantibodies targeting an extra-
cellular pore domain of the KCNQ1 channel were
detected in a subset of patients and were associated
with a shorter QT interval (4). When immunizing rab-
bits against the same target peptide epitope of the
KCNQ1 channel, a shortening of the QT interval and
ventricular effective refractory period could be repro-
duced (5). On the cellular level, cardiomyocytes iso-
lated from the immunized rabbits exhibited shorter
action potential (AP) duration (APD), as well as
increased repolarizing IKs current densities (5).SEE PAGE 2153
MDP = maximum diastolic
potential
V1/2 = half-maximal activation
potential
VT = ventricular
tachyarrhythmiaTaken together, these findings indicate that the
humoral immune response following KCNQ1 peptide
immunization accelerates cardiac repolarization.
However, although reasonable, a causative relation-
ship between circulating KCNQ1 antibodies and the
observed activation of IKs has not yet been established.
Thus, in view of a therapeutic use for patients with a
pathological delay in cardiac repolarization as in LQTS,
the aim of the present study was to: 1) provide evi-
dence for the KCNQ1 antibody–induced IKs activation;
2) explore the biophysical mechanisms by which
KCNQ1 antibodies enhance KCNQ1 channel function;
and 3) investigate the therapeutic potential of KCNQ1
antibodies in LQTS2 using human induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CMC).
METHODS
KCNQ1 ANTIBODY PURIFICATION. New Zealand
White rabbits were immunized against the extracel-
lular peptide sequence of the KCNQ1 channel, as
previously described, and anti-KCNQ1 IgG were
affinity-purified (Davids Biotechnologie, Regensburg,
Germany, and ProteoGenix, Schiltigheim, France) (5).
Of note, the concentration (30 mg/ml) used for our
in vitro experiments was based on the estimated
average amount of circulating immunoglobulin G
(IgG) found in immunized rabbits.
MAMMALIAN CELL CULTURE AND PATCH CLAMP
RECORDINGS. Chinese hamster ovary (CHO) cells
stably expressing the subunits KCNQ1/KCNE1 under-
lying human IKs were used. To study the interaction
between KCNQ1 antibodies and the other major hu-
man cardiac ion channels, CHO (Nav1.5, hERG) and
human embryonic kidney (HEK) 293 cells (Cav1.2)stably expressing the respective channels
were applied. More details on cell preparation
methods are provided in the Supplemental
Appendix. Macroscopic and single-channel
currents were recorded at room temperature
using an EPC-10 amplifier controlled by
PATCHMASTER software version 2x90.5
(HEKA Elektronik, Lambrecht, Germany) on
cells after 24 h of incubation with KCNQ1
antibodies at 2 different concentrations
(30 mg/ml, 60 mg/ml) and compared with
control conditions. A detailed Methods sec-
tion regarding the patch clamp protocol is
given in the Supplemental Appendix.
COMPUTER SIMULATIONS. We adopted the
mathematical model proposed by Ten
Tusscher-Noble-Noble-Panfilov to simulate
the effects of KCNQ1 antibodies on the AP of
human ventricular cardiomyocytes and on the
QT in pseudo-ECGs (Supplemental Appendix).
hiPSC-CMC CELL CULTURE AND PATCH
CLAMP RECORDINGS. Ventricular car-
diomyocytes differentiated from hiPSCs (Pluricyte
cardiomyocyte, Ncardia BV, Leiden, the Netherlands)
were cultured according to the manufacturer’s in-
structions. To induce a pharmacological LQTS2, hiPSC-
CMCs were challenged with 25 nmol/l E-4031 (Alo-
mone Labs, Jerusalem, Israel). In addition, hiPSC-
CMCs derived from a patient with congenital LQTS2
(subsequently referred to as hiPSC-CMC-LQTS2) were
used. Information on the donor patient’s phenotype
and his hiPSC reprogramming and validation can be
found in the Supplemental Appendix. The amphoter-
icin B–perforated patchmethodwas used to record APs
under current-clamp conditions 24-h KCNQ1 anti-
bodies. Details on the patch clamp protocol used are
described in the Supplemental Appendix.
STATISTICAL ANALYSES. One-way analysis of vari-
ance was used to assess for differences between
groups for normally distributed data, followed by
Tukey’s multiple comparisons test. For the compari-
son between 2 group means, 2-tailed Student’s t-test
was performed after the Shapiro-Wilk test asserted a
normal distribution of the samples. The Mann-
Whitney U test determined the statistical significance
of non-normally distributed data. Analysis of cate-
gorical variables was carried out using chi-square
contingency tables. A p value <0.05 was considered
statistically significant. It should be noted that the
p values presented in this report have not been
adjusted for multiplicity, and therefore, inferences
drawn from these statistical tests may not be repro-
ducible. GraphPad Prism 7 software (GraphPad
FIGURE 1 Effect of KCNQ1 Antibodies on IKs
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Representative IKs current traces recorded in Chinese hamster ovary cells under the control condition (A, cell capacitance 12.8 pF) and in the
presence of 30 mg/ml (B, 14.7 pF) and 60 mg/ml (C, 17.4 pF) KCNQ1 antibodies. (D and E) Step and tail current densities as a function of the
test potential. Indicated are mean  SEM, comparing control cells (n ¼ 19), and cells with 30 mg/ml (n ¼ 23) and 60 mg/ml (n ¼ 10) KCNQ1
antibodies. **p < 0.01; ***p < 0.001; ****p < 0.0001 comparing control versus KCNQ1 Ab 60 mg/ml. Ab ¼ antibody.
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2142Software, La Jolla, California) was used for statisti-
cal analyses.
RESULTS
KCNQ1 ANTIBODIES INCREASE IKs IN A CONCENTRATION-
DEPENDENT MANNER. We measured the effect of
KCNQ1 antibodies on activating IKs step currents un-
der voltage-clamp conditions using 3-s depolarizing
pulses applied in 10 mV incremental steps
from 50 mV to þ70 mV from a holding potentialof 60 mV. After each test pulse, the membrane was
repolarized to 40 mV to record the deactivating
IKs tail currents. KCNQ1 antibodies significantly
increased IKs (Figures 1A to 1C). At a concentration
of 60 mg/ml, a 1.7-fold increase in mean IKs step
current density at þ70 mV (from 271.1  35.1 pA/pF to
466.1  61.7 pA/pF; p < 0.0001) could be observed, as
well as a 2.3-fold increase in mean IKs tail current
density after depolarization to þ70 mV (from 45.9 
6.3 pA/pF to 103.6  13.5 pA/pF; p < 0.0001). There
were no statistical differences in cell capacitance
FIGURE 2 Effect of KCNQ1 Antibodies on the Biophysical Properties of IKs Channels
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Indicated are mean  SEM. (A) Voltage-dependent activation of IKs. Control n ¼ 19 (V1/2 ¼ 16.7  0.9 mV, slope factor k ¼ 18.5  0.8 mV), KCNQ1 Ab
30 mg/ml n ¼ 23 (V1/2 ¼ 6.7  0.5 mV, k ¼ 17.4  0.5 mV), KCNQ1 Ab 60 mg/ml n ¼ 10 (V1/2 ¼ 11.4  1.1 mV, k ¼ 15.2  1.0 mV). p < 0.0001 when
comparing V1/2 between control versus KCNQ1 Ab 30 mg/ml and 60 mg/ml. p < 0.05 when comparing the slope factor k of control cells versus KCNQ1 Ab
60 mg/ml. (B) Voltage-dependent deactivation of IKs. Control n ¼ 19 (V1/2 ¼ 4.6  0.8 mV, k ¼ 18.1  0.7 mV), KCNQ1 Ab 30 mg/ml n ¼ 23 (V1/2 ¼ 0.1 
0.7 mV, k ¼ 15.7  0.6 mV), KCNQ1 Ab 60 mg/ml n ¼ 10 (V1/2 ¼ 19.8  1.3 mV, k ¼ 12.0  1.1 mV). p < 0.0001 when comparing V1/2 between control
versus KCNQ1 Ab 30 mg/ml and 60 mg/ml, respectively. p < 0.05 when comparing the slope factor k between control versus KCNQ1 Ab 30 mg/ml and
60 mg/ml, respectively. Ab ¼ antibody.
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2143between groups (Supplemental Figure 1). The slightly
dampened IKs current densities of cells treated with
KCNQ1 antibodies recorded at higher depolarizing
potentials most likely result from reduced driving
force for Kþ efflux due to extracellular Kþ accumu-
lation. As shown on the representative IKs current
traces in Figures 1B and 1C, a prominent instanta-
neous current component could be discerned in the
presence of KCNQ1 antibodies (6). At the test po-
tential of 50 mV, an inward current could be
recorded in CHO cells treated with the 60 mg/ml
KCNQ1 antibodies, suggesting an altered selectivity
for ions other than Kþ, a phenomenon not observed
when 30 mg/ml KCNQ1 antibodies were applied
(Figures 1D and 1E). Both the considerable instanta-
neous current component and the inward current at
a potential above the reversal potential for Kþ sug-
gest an accumulation of channels in the open state
due to KCNQ1 antibodies.
KCNQ1 ANTIBODIES SHIFT THE VOLTAGE-DEPENDENCE
OF ACTIVATION AND SLOW DEACTIVATION OF IKs.
KCNQ1 antibodies (30 mg/ml) shifted the half-maximal
activation potential (V1/2) by 10 mV compared with
control cells (p < 0.0001) without manifest effect on
the slope factor k (Figure 2A). With 60 mg/ml KCNQ1
antibodies, IKs currents were activated at more
negative potentials (V1/2 ¼ 11.4  1.1 mV comparedwith control cells 16.7  0.9 mV; p < 0.0001) and the
voltage sensitivity was increased (k ¼ 15.2  1.0 mV
with 60 mg/ml KCNQ1 antibodies vs. 18.5  0.8 mV for
control cells; p < 0.05). Similarly, a concentration of
60 mg/ml KCNQ1 antibodies shifted the voltage
dependence of deactivation to more negative poten-
tials by 24.4 mV (p < 0.0001) (Figure 2B). These re-
sults suggest that 1 mechanism of the IKs increase by
KCNQ1 antibodies is the modulation of voltage
sensitivity of the channel.
The time constants of IKs activation were best
described by a biexponential function (Supplemental
Figure 2A). Both fast (sfast) and slow (sslow) compo-
nents of activation differed in the presence of KCNQ1
antibodies. A leftward shift could be distinguished in
the voltage dependence of time constants, consistent
with the V1/2 shift of activation curves. When the
voltage-dependent time constants were shifted by
10 mV to match peak time constants, both fast and
slow components of activation become super-
imposed, thus indicating that KCNQ1 antibodies do
not affect the IKs channel kinetics per se
(Supplemental Figure 2B). The low IKs tail current
amplitude made a reliable fit to estimate the deacti-
vation time constants difficult (Supplemental
Figure 2C). As the kinetics of deactivation could not
be reliably discriminated, we estimated the channel
availability at the end of the 40 mV pulse as the
FIGURE 3 Effect of KCNQ1 Antibodies on IKs Using a Protocol With a Prolonged Deactivation Phase
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Represented are mean  SEM. *p < 0.05 when comparing the normal versus long deactivation protocol. (A and B) Step and tail current densities as a
function of the test potential. (C) Voltage-dependent activation of IKs. Control (V1/2 ¼ 16.7  0.9 mV, slope factor k ¼ 18.5  0.8 mV), KCNQ1 Ab
30 mg/ml (V1/2 ¼ 6.7  0.5 mV, k ¼ 17.4  0.5 mV) versus KCNQ1 Ab 30 mg/ml long deactivation protocol (V1/2 ¼ 6.3  0.9 mV, k ¼ 19.2  0.8 mV).
(D) Voltage-dependent deactivation of IKs. Control (V1/2 ¼ 4.6  0.8 mV, k ¼ 18.1  0.7 mV), KCNQ1 Ab 30 mg/ml (V1/2 ¼ 0.1  0.7 mV, k ¼ 15.7 
0.6 mV) versus KCNQ1 Ab 30 mg/ml long deactivation protocol (V1/2 ¼ 1.8  1.1 mV, k ¼ 18.9  1.0 mV). The long deactivation protocol did not affect
the leftward V1/2 shift occurring in the presence of 30 mg/ml KCNQ1 antibodies (p < 0.01 when comparing control versus KCNQ1 Ab with either pulse
protocol). The slope factors were not significantly different. Ab ¼ antibody.
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FIGURE 4 Effect of KCNQ1 Antibodies on Single-Channel IKs
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(A) Representative single-channel current traces from nontransfected Chinese hamster ovary (CHO) cells (tip resistance 18 MU) and CHO KCNQ1þ/KCNE1þ cells with
30 mg/ml KCNQ1 antibodies (20 MU, 2 active channels within the patch), 60 mg/ml (29 MU, 9 active channels within the patch) and without antibodies (27 MU, 6 active
channels within the patch). Ensemble-averaged currents of successive recordings of representative cells under the control condition (31 sweeps) versus treatment with
30 mg/ml (40 sweeps) and 60 mg/ml KCNQ1 antibodies (46 sweeps). (B) The current amplitudes were plotted against pulse potentials between 0 mV and þ40 mV in
20 mV incremental steps. The amplitude–voltage relationship resulted in an estimated slope conductance of 2.6 pS for control cells (n¼ 7), 2.7 pS and 4.9 pS for cells
treated with KCNQ1 antibodies 30 mg/ml (n ¼ 7) and 60 mg/ml (n ¼ 10), respectively. (C) The bars represent the mean  SEM open and closed dwell times (recorded
at þ40 mV) for control cells (n ¼ 6) and cells treated with 30 mg/ml (n ¼ 5) and 60 mg/ml KCNQ1 antibodies (n ¼ 7). (D) Represented is the mean  SEM open
probability (recorded at þ40 mV) in control cells (n ¼ 6) compared with cells with 30 mg/ml (n ¼ 5) and 60 mg/ml KCNQ1 antibodies (n ¼ 7). *p < 0.05; **p < 0.01.
Ab ¼ antibody; Po ¼ open probability.
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2145ratio (amplitude at the end of the tail current)/
(amplitude at the beginning of the tail current)
(Supplemental Figure 3). The fractions were markedly
increased in cells treated with 60 mg/ml KCNQ1 anti-
bodies compared with control cells. Because the tail
currents did not deactivate completely during the 2-s
return potential of 40 mV, we modified the pulseprotocol by prolonging the repolarizing pulse to 6 s
(long deactivation protocol) to better estimate to what
extent the slowing of deactivation is contributing to
the increase of the IKs amplitude. When enough time
was allowed for the IKs channels to deactivate
completely, the ratio of nondeactivated IKs channels
decreased accordingly (Supplemental Figure 3).
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the IKs current density increase measured with KCNQ1
antibodies (30 mg/ml) converges toward the control
condition (Figures 3A and 3B), but the voltage-
dependent activation and deactivation remained
shifted (Figures 3C and 3D). The net effect is that
KCNQ1 antibodies have a dual effect on IKs channels:
they modulate the voltage sensitivity of the channel
and markedly slow the deactivation. This latter pro-
cess could lead to accumulation of activated channels
and thus further contribute to the increased activa-
tion during the next test pulse. Our experiments with
the higher IgG concentration (60 mg/ml) further sup-
port these findings (Supplemental Figure 4): whereas
a prolongation of the deactivation phase allows the
IKs current densities of KCNQ1 antibody–treated
(30 mg/ml) cells to return to normal (Figure 3A and 3B),
in the presence of 60 mg/ml KCNQ1 antibodies, not
enough time is allowed for the channels to deactivate
completely between pulses. Accordingly, the propor-
tion of nondeactivated IKs channels with 60 mg/ml after
6 s of repolarization to 40 mV diminished, but
without reaching values observed under control con-
ditions (Supplemental Figure 3). Longer repolarizing
pulses were avoided to minimize extracellular Kþ
accumulation (7).
KCNQ1 ANTIBODIES INCREASE OPEN TIME AND
PROBABILITY OF IKs CHANNELS. To investigate the
molecular mechanisms of KCNQ1 antibodies on IKs
gating, we performed single-channel recordings in
CHO KCNQ1þ/KCNE1þ cells comparing control condi-
tions with cells exposed to KCNQ1 antibodies. Over
the course of 50 sweeps at þ40 mV for 4,000 ms, si-
lent sweeps without channel activity prevailed in the
recordings of control cells, supporting the previous
observation that KCNQ1 channels open with a signif-
icant delay (8). However, when KCNQ1 antibodies
were applied to the CHO cells, rapid flickering became
apparent (Figure 4A). On average, the single-channel
current at þ40 mV was estimated at 0.36  0.03 pA
for the control cells, and 0.38  0.07 pA and 0.34 
0.04 pA for CHO cells treated with 30 mg/ml and
60 mg/ml KCNQ1 antibodies, respectively. Non-
transfected CHO cells lack any appreciable endoge-
nous currents as shown in Figure 4A. From recordings
at 3 different voltages, a linear fit yielded a value of
2.6 pS for the single-channel conductance under
control conditions, which is in line with the published
reports (8,9). The linear fit crosses the x-axis at the
reversal potential expected for Kþ-selective channels.
Similar values were found in the presence of 30 mg/ml
KCNQ1 antibodies, with a single-channel conductanceof 2.7 pS. With 60 mg/ml KCNQ1 antibodies, the
single-channel conductance was estimated at 4.9 pS
(Figure 4B). Extrapolating to zero-current amplitude,
the reversal potential was calculated at 30 mV, a
value well above the equilibrium potential for Kþ,
indicating an altered ion selectivity in the presence of
a high concentration of KCNQ1 antibodies. The mean
open dwell time significantly rose from 2.9  0.4 ms
to 4.8  0.7 ms and 5.6  0.8 ms in the presence of
30 mg/ml and 60 mg/ml KCNQ1 antibodies, respec-
tively (p < 0.05) (Figure 4C). At the same time, the
mean closed dwell time decreased from 10.2  1.4 ms
to 7.6  2.3 ms and 6.9  0.6 ms in the presence of
30 mg/ml and 60 mg/ml KCNQ1 antibodies, respec-
tively (p < 0.05) (Figure 4C). In addition, the open
probability increased by 2-fold when cells were
exposed to 60 mg/ml KCNQ1 antibodies (p < 0.01)
(Figure 4D). Taken together, the single-channel
kinetics are in accordance with the macroscopic
IKs findings.
KCNQ1 ANTIBODIES DO NOT AFFECT KCNQ1 CHANNEL
EXPRESSION. Because a change in KCNQ1 channel
expression may influence the amplitude of IKs, we
performed qPCR and Western blot experiments to
quantify the channels comparing cells in the presence
and absence of KCNQ1 antibodies. Incubation of CHO
cells with KCNQ1 antibodies did not affect the relative
expression of KCNQ1 mRNA nor the channel protein
amount (Supplemental Figure 5).
KCNQ1 ANTIBODIES ARE SPECIFIC TO IKs CHANNELS. To
address the question of off-target effects of KCNQ1
antibodies, we performed patch clamp experiments
on mammalian cell lines stably expressing the other
human cardiac voltage-gated ion channels that
essentially shape the cardiac action potential, that is,
CHO Nav1.5, HEK 293 Cav1.2, and CHO hERG. We
observed no changes in biophysical properties of the
Nav1.5, Cav1.2, and hERG channels in the presence of
KCNQ1 antibodies (Supplemental Figure 6).
KCNQ1 ANTIBODIES SHORTEN APD AND THE QT
INTERVAL IN AN IN SILICO MODEL OF HUMAN
CARDIOMYOCYTE LQTS2. The effects of the shift of
the steady-state activation relationship of IKs were
evaluated in computer simulations using the Ten
Tusscher-Noble-Noble-Panfilov human ventricular
cell model. Supplemental Figure 7 shows the effects
of shifting this relationship by 10 mV, corresponding
to the shift observed in patch clamp experiments with
30 mg/ml KCNQ1 antibody. This shift shortened the AP
in all simulated genotypes (wild-type, heterozygous,
and homozygous LQTS2) and in all 3 ventricular cell
types (Supplemental Figure 7A). Importantly, in the
FIGURE 5 Effect of KCNQ1 Antibodies on hiPSC-CMC
B
600
800 n.s.
***
AP
D 9
0 
(m
s)
200
400
0
*
Co
ntr
ol
KC
NQ
1 A
b 3
0 μ
g/m
l
KC
NQ
1 A
b 6
0 μ
g/m
l
KCNQ1
Ab 30 μg/ml 0 mV
KCNQ1
Ab 60 μg/ml 0 mV
Control 0 mV
500 ms2
0 
m
VA
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2147epicardial and endocardial cell models at all basic
cycle lengths, the APD shortening compensated
almost fully the APD prolongation induced by the
simulated heterozygous LQTS2 (Supplemental
Figure 7B). These effects were more prominent with
a shift of the steady-state IKs activation relationship
by 28.1 mV, corresponding to 60 mg/ml antibody
concentration (Supplemental Figure 8). In particular,
this shift compensated the APD prolongation caused
by the simulated homozygous LQTS2 in epicardial
and endocardial cells and the APD prolongation
caused by the simulated heterozygous LQTS2 in mid-
myocardial cells. The effects of shifting the steady-
state activation relationship of IKs by 10 mV are
further detailed in Supplemental Figure 7C, in which
the time courses of IKs and IKr are shown jointly with
the APs of an epicardial cell paced at a basic cycle
length of 1,000 ms. The reduction of IKr in the het-
erozygous and homozygous LQTS2 genotypes
induced an increase of IKs (repolarization reserve),
which was augmented by the simulated effect of the
KCNQ1 antibodies, contributing to the normalization
of APD. This effect was considerably more prominentwith a shift by 28.1 mV (Supplemental Figure 8). In a
transmural model of conduction, shifting the activa-
tion relationship of IKs to more negative potentials
shortened the QT interval in pseudo-ECGs for all 3
genotypes (Supplemental Figure 7D). Of note, the
shift by 28.1 mV almost fully normalized the QT
interval in the simulated heterozygous LQTS2 geno-
type. These results, therefore, support the notion that
by its effect on IKs, KCNQ1 antibodies may compen-
sate APD and thus QT-interval prolongation in
patients afflicted by LQTS2.
KCNQ1 ANTIBODIES SHORTEN APD IN IN VITRO
MODELS OF HUMAN CARDIOMYOCYTE LQTS2. With
this hypothesis in mind, we next tested whether
KCNQ1 antibodies accelerate cardiac repolarization in
hiPSC-CMCs. As shown in Figure 5, KCNQ1 antibodies
caused a concentration-dependent shortening of the
APD determined at 90% repolarization (APD90) at 37C
(p < 0.001) (Supplemental Table 1). In conjunction
with the experimental conditions of CHO cells, patch
clamp recordings were also carried out at room tem-
perature. At temperatures below the physiological
level, the spontaneous APs of hiPSC-CMCs are
FIGURE 6 Effect of KCNQ1 Antibodies on hiPSC-CMC-LQTS2
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2148necessarily prolonged. Nevertheless, the KCNQ1 an-
tibodies significantly shortened the APD90 by 21% at
30 mg/ml and by 40% at 60 mg/ml concentration,
respectively (Supplemental Figure 9, Supplemental
Table 2). E-4031, a selective KCNH2 Kþ channel
blocker, was used to create a pharmacological model
of LQTS2. The application of E-4031 caused a 4-fold
increase in APD90 and induced APD alternans as
well as early afterdepolarizations (EADs)
(Supplemental Figure 10). KCNQ1 antibodies at bothconcentrations shortened the APD and significantly
reduced the incidence of arrhythmic events (p < 0.05)
(Supplemental Figure 10, Supplemental Table 3).
Next, we studied the effect of KCNQ1 antibodies on
congenital LQTS2 using hiPSC-CMCs from a patient
with an A561P mutation in the KCNH2 gene. HiPSC-
CMC-LQTS2 presented markedly prolonged APs
(mean APD90 1,033  547.4 ms) and developed
frequent arrhythmic events in terms of EADs,
arrhythmic beating and beating arrest (Figure 6).
CENTRAL ILLUSTRATION KCNQ1 Antibodies Activate IKs Channels
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KCNQ1 antibodies activate IKs channels to shorten action potential duration and to suppress arrhythmias in a cellular model of long QT
syndrome type 2.
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2149Treatment with KCNQ1 antibodies completely
reversed the pathological and proarrhythmogenic AP
lengthening of LQTS2 (mean APD90 289.7  12.9 ms
and 284.2  17.2 ms with 30 and 60 mg/ml, respec-
tively; p < 0.001) (Supplemental Table 4) and abol-
ished all arrhythmic activities (Figure 6). Of note, in
the presence of 60 mg/ml KCNQ1 antibodies, we found
a less negative maximum diastolic potential (MDP) of
hiPSC-CMCs and hiPSC-CMC-LQTS2 (Supplemental
Tables 1 and 4). This depolarization of the MDP is
possibly driven by a net inward current induced by
KCNQ1 antibodies at the higher concentration,
consistent with the inward current recorded in CHO
cells at 60 mg/ml, but not 30 mg/ml, antibody con-
centration at the test potential of 50 mV. As KCNQ1
antibody-induced IKs activation shortens APD, the
beating rate of cardiomyocytes necessarily increasedand explains our observation of higher frequencies
when exposed to KCNQ1 antibodies (Supplemental
Tables 1 to 4)
DISCUSSION
Patients with LQTS are predisposed to VT and sudden
cardiac death (1). Current treatment options for LQTS
include beta-blockers, the implantation of a
cardioverter-defibrillator and the left cardiac sympa-
thetic denervation (3). However, there is a substantial
interest and well-recognized need for developing
specific drugs able to activate the repolarizing cur-
rents in order to normalize the abnormally prolonged
repolarization of the heart in LQTS. This is particu-
larly true for LQTS patients who enter periods of
electrical storms resistant to standard therapy with
FIGURE 7 Model of the KCNQ1 Channel Tetramer (PDB: 5VMS)
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(A) Top view of the IKs channel. (B) Side view of the IKs channel. (C) Model of 1 subunit of the IKs channel, the transmembrane segments S1 to
S6 are labeled (PyMol Molecular Graphics System, v2.0.7 Schrödinger, New York, New York). The targeted peptide sequence (blue) and
selectivity filter (green) are highlighted. Ab ¼ antibody.
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2150repeated defibrillation shocks and increased mortal-
ity (2). Moreover, patients with the type 2 form of
LQTS respond less well to conventional treatment
than LQTS1 individuals (10–15). In the present study,
we provided the first proof of concept that purified
KCNQ1 antibodies act as agonists on the IKs channel
(Central Illustration). We found a concentration-
dependent response: doubling the KCNQ1 antibody
concentration increased the IKs current density by
2-fold in CHO KCNQ1þ/KCNE1þ cells. Patch clamp re-
cordings disclosed a dual effect of KCNQ1 antibodies:
a negative shift in voltage sensitivity and a marked
slowing of IKs channel deactivation. To better un-
derstand the mechanisms underlying the IKs increase,
we performed single-channel recordings. At þ40 mV,
IKs activation is near maximal in both conditions
(control vs. KCNQ1 antibodies). We therefore chose to
study single-channel behavior at this particular po-
tential, thereby reducing the impact of the shift in
activation. In the presence of 60 mg/ml KCNQ1 anti-
bodies, we found that the observed gain of function
of KCNQ1 channels results mainly from an increased
mean open dwell time as well as open probability, in
addition to the shift in activation. The contribution of
the single-channel conductance to the IKs increase is
less evident, because it is essentially the consequence
of a shift in reversal potential reflecting a change in
ion selectivity. In line with this observation, an in-
ward current could be recorded at the whole-cell level
at a potential below the shifted reversal potential inthe presence of 60 mg/ml KCNQ1 antibodies. As illus-
trated in Figure 7, the peptide sequence targeted by
the KCNQ1 antibodies is located only 8 amino acids
away from the selectivity filter of the IKs channel
(TTIGYGD motif), leading us to reasonably speculate
that KCNQ1 antibodies can alter ion selectivity when
present in high concentrations, potentially due to
steric hindrance (16). When reducing the dose of
KCNQ1 antibodies down to 30 mg/ml, the ion selec-
tivity remained unaffected (equilibrium potential
within normal range for Kþ). With 30 mg/ml KCNQ1
antibodies, the longer mean open dwell time is the
predominant mechanism underlying the observed IKs
increase, whereas the open probability was on
average higher compared with control cells. At a
concentration of 30 mg/ml, KCNQ1 antibodies do not
affect single-channel conductance.
Next, we used a mathematical model to predict the
effect of KCNQ1 antibodies on human ventricular APs,
thereby simulating 3 different genotypes (wild-type,
heterozygous, and homozygous LQTS2). Because
LQTS1 is due to a mutation in the KCNQ1 gene, it
seems unlikely that antibodies targeting these
defective channels would increase IKs. Our in-
vestigations, therefore, focused on LQTS2 that are
more likely to benefit from KCNQ1 antibodies by
compensating for the loss of the IKr repolarizing cur-
rent through IKs up-regulation. In our simulations,
incorporating the shift in steady-state IKs activation
induced by the KCNQ1 antibodies shortened the APD
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: KCNQ1 anti-
bodies activate IKs channels, accelerate ventricular repolariza-
tion, and suppress arrhythmias in an in vitro cellular model of
long QT syndrome.
TRANSLATIONAL OUTLOOK: Clinical studies are now
needed to evaluate the efficacy and safety of KCNQ1 antibodies
in patients with long QT syndrome type 2.
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2151and, most importantly, normalized APD in simulated
LQTS2. Moreover, the shift in steady-state IKs acti-
vation normalized the QT interval of pseudo-ECGs in
a transmural conduction model of heterozygous
LQTS2. The shift of the steady-state activation func-
tion of IKs was sufficient to produce these effects via
enhancement of IKs. In line with these in silico find-
ings, we then studied the therapeutic potential of
KCNQ1 antibodies both in a pharmacological and
congenital model of LQTS2 using hiPSC-CMCs. As
expected, the APD was significantly prolonged in both
experimental LQTS2 models. In addition, we
observed frequent arrhythmic activities of the car-
diomyocytes, well-known precursors of life-
threatening VT in LQTS patients. Treatment with
KCNQ1 antibodies at 30 mg/ml was sufficient to
restore electrical stability in LQTS2. KCNQ1 anti-
bodies normalized the APD, indicating that KCNQ1
antibodies are able to compensate for the prolonged
repolarization caused by IKr inhibition (enhanced
repolarization reserve). Moreover, KCNQ1 antibodies
completely suppressed spontaneous arrhythmias. Of
note, the aforementioned concern of depolarized
MDP is only observed with the higher concentration
of KCNQ1 antibodies. The altered ion selectivity pre-
sumed with 60 mg/ml KCNQ1 antibodies is reasonably
the underlying cause for the depolarization of the
MDP. Because hiPSC-CMCs have an inherent defi-
ciency of the inward rectifier Kþ current IK1, an in-
crease of nonselective ion conductance as with
60 mg/ml KCNQ1 antibodies would result in unopposed
depolarization. With our dynamic clamp system,
electronic IK1 expression established a physiological
resting membrane potential to recapitulate human
mature ventricular cardiomyocytes. In this physio-
logical context, IK1 functionally counterbalances the
changed ion selectivity with 60 mg/ml KCNQ1 anti-
bodies (Supplemental Table 5). This is an important
observation, because in view of a therapeutic applica-
tion, even at the higher concentration, the intrinsic IK1
current of mature cardiomyocytes (as in patients) can
compensate for possible altered ion selectivity.
STUDY LIMITATIONS. In current-clamp experiments,
we were not able to pace the hiPSC-CMCs due to
technical limitations. The maximum stimulus the
EPC-10 amplifier can apply (1 nA/10 ms) is below the
diastolic current threshold for hiPSC-CMCs. The pu-
rified antibodies were polyclonal and not mono-
clonal immunoglobulins. However, in view of the
development of a therapeutic vaccine for the LQTS,
our intent was to prove that the polyclonal antibody
population resulting from immunization is effectiveas IKs activator. Future studies on animal models will
be important to investigate the effect on the whole-
heart level. We do not completely rule out a poten-
tial heart rate acceleration by the KCNQ1 antibodies
in patients with LQTS. Moreover, clinical trials will
be needed to determine the kinetics of antibody
response in humans and to formulate vaccination
protocols to induce and maintain a therapeutic
antibody level.
CONCLUSIONS
Taken together, this is the first proof-of-concept
study providing evidence that KCNQ1 antibodies are
potent IKs activators. We elucidated the mechanisms
of action of KCNQ1 antibodies on the single-channel
level. Moreover, we demonstrated the therapeutic
potential of KCNQ1 antibodies by enhancing repolar-
ization reserve and restoring electrical stability in
LQTS2. In contrast to previous studies on antibodies
with almost exclusively inhibitory effects on chan-
nels, the KCNQ1 antibody is unique in its kind
because it induces a gain-of-function of the KCNQ1
channel. KCNQ1 antibody therapy thus presents an
innovative, unprecedented treatment approach for
patients with LQTS (17).
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